Antitumor activity of tripterine via cell-penetrating peptide-coated nanostructured lipid carriers in a prostate cancer model

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 4339-4350

  Yuan, Ling ^a   Liu, Cong Yan ^b   Chen, Yan ^b   Zhang, Zhen Hai ^b   Zhou, Lei ^a   Qu, Ding ^b  

^a JIANGSU UNIVERSITY   (China)

^b KEY LABORATORY OF NEW DRUG DELIVERY SYSTEM OF CHINESE MATERIA MEDICA   (China)

Author keywords

Antitumor activity; Cell penetrating peptide; Nanostructured lipid carriers; Prostate cancer; Tripterine

Indexed keywords

ANTINEOPLASTIC AGENT; CELL PENETRATING PEPTIDE COATED TRIPTERINE LOADED NANOSTRUCTURED LIPID CARRIER; CYCLOPHOSPHAMIDE; INTERLEUKIN 6; TRIPTERINE; TRIPTERINE LOADED NANOSTRUCTURED LIPID CARRIER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; HUMAN; HUMAN CELL; HYDROPHILICITY; IC 50; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NICK END LABELING; NONHUMAN; PROSTATE CARCINOMA; TUMOR NECROSIS;

ANTITUMOR ACTIVITY; CELL-PENETRATING PEPTIDE; NANOSTRUCTURED LIPID CARRIERS; PROSTATE CANCER; TRIPTERINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL-PENETRATING PEPTIDES; DRUG CARRIERS; HUMANS; IN SITU NICK-END LABELING; INTERLEUKIN-6; LIPIDS; MALE; MICE; MICE, INBRED C57BL; NANOSTRUCTURES; PROSTATIC NEOPLASMS; TRITERPENES; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887325602     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S51621     Document Type: Article

References (31)

1. Kannaiyan R, Shanmugam MK, Sethi G. Molecular targets of celastrol derived from thunder of god vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett. 2011;303(1):9-20.
2. Liu XP, Zhou ST, Li XY, et al. Antitumor activity of N-trimethyl chitosan-encapsulated camptothecin in a mouse melanoma model. J Exp Clin Cancer Res. 2010;29:76.
3. Guo QL, You QD, Wu ZQ, Yuan ST, Zhao L. General gambogic acids inhibited growth of human hepatoma SMMC-7721cells in vitro and in nude mice. Acta Pharmacol Sin. 2004;25(6):769-774.
4. Jang SY, Jang SW, Ko J. Celastrol inhibits the growth of estrogen positive human breast cancer cells through modulation of estrogen receptor α. Cancer Lett. 2011;300(1):57-65.
5. Mou H, Zheng Y, Zhao P, et al. Celastrol induces apoptosis in non-small-cell lung cancer A549cells through activation of mitochondria-and Fas/FasL-mediated pathways. Toxicol In Vitro. 2011;25(5):1027-1032.
6. Rajendran P, Li F, Shanmugam MK, et al. Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2signaling cascade in vitro and in vivo. Cancer Prev Res (Phila). 2012;5(4):631-643.
7. Ge P, Ji X, Ding Y, et al. Celastrol causes apoptosis and cell cycle arrest in rat glioma cells. Neurol Res. 2010;32(1):94-100.
8. Lee JH, Won YS, Park KH, et al. Celastrol inhibits growth and induces apoptotic cell death in melanoma cells via the activation ROS-dependent mitochondrial pathway and the suppression of PI3K/AKT signaling. Apoptosis. 2012;17(12):1275-1286.
9. Dai Y, DeSano J, Tang W, et al. Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB. PLoS One. 2010;5(12): e14153.
10. Liu Z, Ma L, Zhou GB. The main anticancer bullets of the Chinese medicinal herb, thunder god vine. Molecules. 2011;16(6):5283-5297.
11. Liu D, Liu Z, Wang L, Zhang C, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces. 2011;85(2):262-269.
12. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech. 2011;12(1):62-76.
13. Des Rieux A, Fievez V, Momtaz M, et al. Helodermin-loaded nanoparticles: characterization and transport across an in vitro model of the follicle-associated epithelium. J Control Release. 2007;118(3): 294-302.
14. Hayashi Y, Yamauchi J, Khalil IA, Kajimoto K, Akita H, Harashima H. Cell penetrating peptide-mediated systemic siRNA delivery to the liver. Int J Pharm. 2011;419(1-2):308-313.
15. Juliano RL, Alam R, Dixit V, Kang HM. Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1(3):324-335.
16. Furukawa R, Yamada Y, Takenaga M, Igarashi R, Harashima H. Octaarginine-modified liposomes enhance the anti-oxidant effect of lecithinized superoxide dismutase by increasing its cellular uptake. Biochem Biophys Res Commun. 2011;404(3):796-801.
17. Fotin-Mleczek M, Fischer R, Brock R. Endocytosis and cationic cell-penetrating peptides-a merger of concepts and methods. Curr Pharm Des. 2005;11(28):3613-3628.
18. Duchardt F, Fotin-Mleczek M, Schwarz H, Fischer R, Brock R. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic. 2007;8(7):848-866.
19. Tyagi M, Rusnati M, Presta M, Giacca M. Internalization of HIV-1 that requires cell surface heparan sulfate proteoglycans. J Biol Chem. 2001;276(5):3254-3261.
20. Yezhelyev MV, Qi L, O'Regan RM, Nie S, Gao X. Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging. J Am Chem Soc. 2008;130(28):9006-9012.
21. Rothbard JB, Garlington S, Lin Q, et al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med. 2000;6(11):1253-1257.
22. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999;285(5433):1569-1572.
23. Liu J, Li H, Chen D, et al. In vivo evaluation of novel chitosan graft polymeric micelles for delivery of paclitaxel. Drug Deliv. 2011;18(3): 181-189.
24. Chen Y, Yuan L, Zhou L, Zhang ZH, Cao W, Wu Q. Effect of cell-penetrating peptide-coated nanostructured lipid carriers on the oral absorption of tripterine. Int J Nanomedicine. 2012;7:4581-4591.
25. Li Z, Wu X, Li J, et al. Antitumor activity of celastrol nanoparticles in a xenograft retinoblastoma tumor model. Int J Nanomedicine. 2012;7: 2389-2398.
26. Kohane DS. Microparticles and nanoparticles for drug delivery. Biotechnol Bioeng. 2007;96(2):203-209.
27. Hirose H, Takeuchi T, Osakada H, et al. Transient focal membrane deformation induced by arginine-rich peptides leads to their direct penetration into cells. Mol Ther. 2012;20(5):984-993.
28. Ziegler A. Thermodynamic studies and binding mechanisms of cell-penetrating peptides with lipids and glycosaminoglycans. Adv Drug Deliv Rev. 2008;60(4-5):580-597.
29. González-Mira E, Nikolić S, García ML, Egea MA, Souto EB, Calpena AC. Potential use of nanostructured lipid carriers for topical delivery of flurbiprofen. J Pharm Sci. 2011;100(1):242-251.
30. Zhang T, Hamza A, Cao X, et al. A novel Hsp90inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther. 2008;7(1):162-170.
31. Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine, " is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 2006;66(9):4758-4765.